Iron Chelation Therapy for Myelodysplastic Syndrome: If and When

Tefferi, Ayalew
February 2006
Mayo Clinic Proceedings;Feb2006, Vol. 81 Issue 2, p197
Academic Journal
The article comments on the use oral chelating agent for treatment of myelodysplastic syndrome (MDS). The iron chelating agent approved by the U.S. Food and Drug Administration was subcutaneously infused deferoxamine. Most patients with MDS are dependent on red blood cell transfusions and are vulnerable to life-threatening end-organ damage from excess tissue iron deposition. Iron chelation therapy is used to treat leukemic transformation and infection in these patients.


Related Articles

  • Red Blood Cell Transfusion Independence Following the Initiation of Iron Chelation Therapy in Myelodysplastic Syndrome. Badawi, Maha A.; Vickars, Linda M.; Chase, Jocelyn M.; Leitch, Heather A. // Advances in Hematology;2010, Vol. 2010, p1 

    Iron chelation therapy is often used to treat iron overload in patients requiring transfusion of red blood cells (RBC). A 76- year-old man with MDS type refractory cytopenia with multilineage dysplasia, intermediate-1 IPSS risk, was referred when he became transfusion dependent. He declined...

  • Biological Basis of Novel Therapies for Myelodysplastic Syndrome. Attar, Eyal C.; Ballen, Karen K. // Current Cancer Therapy Reviews;2006, Vol. 2 Issue 3, p199 

    Myelodysplastic syndrome (MDS) represents a group of malignant clonal disorders characterized by ineffective hematopoiesis and an accumulation of hematopoietic precursors in the bone marrow, frequently resulting in transformation to acute leukemia and death. However, recent understanding of MDS...

  • Myelodysplasia. Heaney, Mark L.; Golde, David W. // New England Journal of Medicine;05/27/99, Vol. 340 Issue 21, p1649 

    Discusses myelodysplastic syndromes. The hematopoietic stem cell; History and classification; Pathology; Diagnosis on morphologic findings with evidence of impaired hematopoiesis; Clinical manifestations of myelodysplastic conditions such as bruising and fatigue; Treatment with chemotherapy,...

  • Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. Matheny, Christina J; Speck, Maren E; Cushing, Patrick R; Zhou, Yunpeng; Corpora, Takeshi; Regan, Michael; Newman, Miki; Roudaia, Liya; Speck, Caroline L; Ting-Lei Gu; Griffey, Stephen M; Bushweller, John H; Speck, Nancy A // EMBO Journal;2/14/2007, Vol. 26 Issue 4, p1163 

    Monoallelic RUNX1 mutations cause familial platelet disorder with predisposition for acute myelogenous leukemia (FPD/AML). Sporadic mono- and biallelic mutations are found at high frequencies in AML M0, in radiation-associated and therapy-related myelodysplastic syndrome and AML, and in isolated...

  • Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study. Benesch, M.; McDonald, G. B.; Schubert, M.; Appelbaum, F. R.; Deeg, H. J. // Bone Marrow Transplantation;Dec2003, Vol. 32 Issue 11, p1071 

    Summary:The objective of this prospective study was to determine whether amifostine (Ethyol®) reduced conditioning-related toxicity following a regimen of busulfan (7?mg/kg) and fractionated total body irradiation (6 × 200?cGy). In all, 12 patients with advanced myelodysplastic syndrome...

  • Managing myelodysplastic syndromes in very old patients: a teaching case report. Niscola, Pasquale; Palombi, Massimiliano; Trawinsk, Malgorzata Monika; Tendas, Andrea; Giovannini, Marco; Scaramucci, Laura; Perrotti, Alessio; de Fabritiis, Paolo // Clinical Interventions in Aging;2013, Vol. 8, p391 

    The introduction of hypomethylating agents in the treatment of myelodysplastic syndromes (MDS) has significantly changed the clinical scenario of these diseases, which afflict predominantly older individuals. However, some concerns regarding the optimal application of these innovative and costly...

  • Mielodisplasia en Pacientes Pediátricos. Evaluación de Clasificaciones Actuales. OYARCE L., VERÓNICA; RODRÍGUEZ Z., NATALIE; TORDECILLA C., JUAN; VERDUGO L., PATRICIA // Revista Chilena de Pediatría;jul/ago2009, Vol. 80 Issue 4, p339 

    Introduction: Myelodysplastic Syndrome (MDS) in pediatrics is a rare and difficult clinical picture to diagnose. Classifications currently in use do not always help in identifying risk factors for leukemic transformation in children. Objective: To evaluate the value of current classifications by...

  • Secondary myelodysplastic syndrome may happen same as paraneoplastic syndrome in a period of time and prior to the appearance of malignancy: A case study of 6 patients. Aznab, Mozaffar; Kavianymoghdam, Kaveh // International Journal of Hematology-Oncology & Stem Cell Researc;Apr2013, Vol. 7 Issue 2, p30 

    Myelodysplastic syndrome is a bone marrow failure in which differentiation and maturity do not happen naturally and dysplasia exists in each of 3 cell categories in Bone marrow. Refractory anemia is one of the major complaints with which the patients come to hematology clinics, which in...

  • Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Giagounidis, A. A. N.; Germing, U.; Strupp, C.; Hildebrandt, B.; Heinsch, M.; Aul, C. // Annals of Hematology;Sep2005, Vol. 84 Issue 9, p569 

    The survival of patients with myelodysplastic syndromes is strongly affected by chromosomal abnormalities. Patients with an isolated del(5q31) have a favourable prognosis that worsens with the addition of another chromosomal abnormality. It has been reported that both patients with isolated...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics